Size | Price | Stock | Qty |
---|---|---|---|
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
CC-90009 (CC90009; Eragidomide) is a novel and potent modulator of cereblon (CRBN), which is part of the cullin 4-RING E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase; CUL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and pro-apoptotic activities. Upon administration, CC-90009 specifically binds to CRBN, thereby affecting the activity of the ubiquitin E3 ligase complex. This leads to the ubiquitination of certain substrate proteins and induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3), which are transcriptional repressors in T-cells. This reduces the levels of these transcription factors, and modulates the activity of the immune system, which may include the activation of T-lymphocytes. In addition, this downregulates the expression of other proteins, including interferon regulatory factor 4 (IRF4) and c-myc, which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.
Targets |
Cereblon
|
---|---|
ln Vitro |
Eragidomide-induced GSPT1 depletion causes acute myeloid leukemia (AML) apoptosis to occur quickly, which lowers leukemia stem cells (LSCs) and leukemia engraftment in large-scale primary patient xenografting of 35 different AML samples. Within AML blasts and LSCs, eragidomide activity is mediated by several tiers of signaling networks and pathways[1].
|
References |
Molecular Formula |
C22H18CLF2N3O4
|
---|---|
Molecular Weight |
461.8458
|
Exact Mass |
461.10
|
Elemental Analysis |
C, 57.21; H, 3.93; Cl, 7.68; F, 8.23; N, 9.10; O, 13.86
|
CAS # |
1860875-51-9
|
Appearance |
Solid powder
|
SMILES |
O=C(NCC1=CC2=C(C(N(C(CC3)C(NC3=O)=O)C2)=O)C=C1)C(F)(C4=CC=C(Cl)C=C4)F
|
InChi Key |
PWBHUSLMHZLGRN-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C22H18ClF2N3O4/c23-15-4-2-14(3-5-15)22(24,25)21(32)26-10-12-1-6-16-13(9-12)11-28(20(16)31)17-7-8-18(29)27-19(17)30/h1-6,9,17H,7-8,10-11H2,(H,26,32)(H,27,29,30)
|
Chemical Name |
2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
|
Synonyms |
CC-90009; CC 90009; CC90009
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 92~100 mg/mL ( 199.19~216.52 mM )
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1652 mL | 10.8260 mL | 21.6521 mL | |
5 mM | 0.4330 mL | 2.1652 mL | 4.3304 mL | |
10 mM | 0.2165 mL | 1.0826 mL | 2.1652 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04297124 | Completed | Drug: CC-90009 Radiation: [14C] |
Healthy Volunteer | Celgene | March 11, 2020 | Phase 1 |
NCT02848001 | Active, not recruiting | Drug: CC-90009 | Leukemia, Myeloid, Acute Myelodysplastic Syndromes |
Celgene | November 14, 2016 | Phase 1 |
NCT04336982 | Active, not recruiting | Drug: CC-90009 Drug: Venetoclax Drug: Azacitidine |
Leukemia, Myeloid, Acute | Celgene | August 5, 2020 | Phase 1 Phase 2 |
CC-90009, a GSPT1-selective cereblon modulator, induces cereblon-and GSPT1-dependent anti-AML activity. [1].Blood. 2021 Feb 4;137(5):661-677. td> |
Identification of genes and pathways modulating the response to CC-90009 via CRIPSR/Cas9 screen. [1].Blood. 2021 Feb 4;137(5):661-677. td> |
Regulation of CRBN splicing and CC-90009 response by the ILF2 and ILF3 complex. [1].Blood. 2021 Feb 4;137(5):661-677. td> |